Search results
Reasons to Hold West Pharmaceutical in Your Portfolio Now - Boston Scientific (NYSE:BSX), DaVita...
Benzinga· 13 hours agoWST is well poised for growth, backed by the robust Proprietary Products segment and sustained...
McKesson (MCK) Reaches 52-Week High: What's Aiding the Stock?
Zacks· 1 day agoInvestors are optimistic about McKesson's (MCK) strength in its Biologics business.
Is Eli Lilly Stock A Buy After FDA Advisors Back Its Alzheimer's Drug?
Investor's Business Daily· 2 days agoThe company also calls for adjusted earnings of $13.50 to $14 a share. Both measures...to bring in...
The Zacks Analyst Blog Highlights Pfizer, Johnson & Johnson and Eli Lilly
Zacks via Yahoo Finance· 21 hours agoSome of these companies are also...obesity, diabetes and Alzheimer's and regular M&A activity will...
Here's How Much a $1000 Investment in Eli Lilly Made 10 Years Ago Would Be Worth Today
Zacks via Yahoo Finance· 20 hours agoIts new tirzepatide medicines, diabetes drug Mounjaro and obesity medicine, Zepbound, are seeing...
Gilead’s Twice-Yearly Shot Prevents HIV. Where the Stock Is Headed.
Barrons.com· 2 days agoDescovy sales were $2 billion in 2023, though the drug is also sold as an HIV treatment. Gilead...
Countries face growing drugs shortage with older medicines among most vulnerable
Euronews via Yahoo News· 4 days agoThe group's annual survey also found that drug shortages affected all European countries in 2023 and...
3 Top Stocks I'd Buy Today and Hold Forever Without Any Hesitation
Motley Fool via Yahoo Finance· 4 days agoBuying a stock with the intention of never selling it, or perhaps only selling it in a few decades,...
Pharma stock in focus after it enters into an agreement with Takeda Pharma for Vonoprazan tablets
Investing.com· 1 day agoWith a market capitalization of Rs. 3,54,085 Crores, the shares of Sun Pharmaceuticals (NS: SUN )...
Gilead Flashes A Bullish Sign After HIV Drug Proves 100% Effective
Investor's Business Daily· 2 days agoHe called the news a "much-needed pipeline win for Gilead." Descovy will lose patent exclusivity in...